Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOGNASDAQ:EPRXNASDAQ:ESLANASDAQ:TIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$9.05-5.5%$6.47$3.75▼$11.40$144.98M2.79102,479 shs57,020 shsEPRXEupraxia Pharmaceuticals$3.94-0.8%$3.63$2.20▼$4.48$141.25M0.6613,119 shs1,169 shsESLAEstrella Immunopharma$1.08+8.6%$0.96$0.63▼$3.23$38.88M0.41124,692 shs86,412 shsTILInstil Bio$30.17-12.3%$17.31$9.62▼$92.00$197.89M1.78168,088 shs367,076 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition-2.25%+13.52%+41.57%+78.54%+956,999,900.00%EPRXEupraxia Pharmaceuticals-2.34%+2.58%-1.00%+0.25%+42.48%ESLAEstrella Immunopharma+18.68%+2.06%-12.39%0.00%+1.02%TILInstil Bio+15.05%+28.60%+144.84%+79.26%+222.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACOGAlpha Cognition1.0265 of 5 stars3.50.00.00.00.00.80.0EPRXEupraxia Pharmaceuticals1.8365 of 5 stars3.71.00.00.01.40.00.6ESLAEstrella Immunopharma2.6262 of 5 stars3.55.00.00.01.81.70.0TILInstil Bio3.5084 of 5 stars3.54.00.00.02.13.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$20.00120.99% UpsideEPRXEupraxia Pharmaceuticals 3.33Buy$10.50166.50% UpsideESLAEstrella Immunopharma 3.00Buy$16.001,388.37% UpsideTILInstil Bio 3.00Buy$119.00294.42% UpsideCurrent Analyst Ratings BreakdownLatest ESLA, ACOG, EPRX, and TIL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$125.00 ➝ $125.006/2/2025TILInstil BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/29/2025ESLAEstrella ImmunopharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.005/22/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$110.00 ➝ $105.005/16/2025ACOGAlpha CognitionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/31/2025ACOGAlpha CognitionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/25/2025ACOGAlpha CognitionRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy3/18/2025ACOGAlpha CognitionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.003/5/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$110.00 ➝ $110.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha Cognition$2.93M49.50N/AN/A($1.08) per share-8.38EPRXEupraxia PharmaceuticalsN/AN/AN/AN/A$0.03 per shareN/AESLAEstrella ImmunopharmaN/AN/AN/AN/A$0.12 per shareN/ATILInstil BioN/AN/AN/AN/A$34.72 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$13.77M-$1.20N/A∞N/AN/AN/A-344.17%8/11/2025 (Estimated)EPRXEupraxia Pharmaceuticals-$28.22M-$0.76N/AN/AN/AN/A-219.64%-96.00%8/6/2025 (Estimated)ESLAEstrella Immunopharma-$7.31M-$0.26N/A∞N/AN/A-195.77%-157.28%N/ATILInstil Bio-$156.09M-$11.97N/AN/AN/AN/A-37.44%-25.08%8/12/2025 (Estimated)Latest ESLA, ACOG, EPRX, and TIL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ACOGAlpha Cognition-$0.58-$0.20+$0.38-$0.13$0.50 million$2.93 million5/13/2025Q1 2025TILInstil Bio-$2.02-$4.32-$2.30-$4.32N/AN/A5/6/2025Q1 2025EPRXEupraxia Pharmaceuticals-$0.19-$0.21-$0.02-$0.21N/AN/A3/31/2025Q4 2024ACOGAlpha Cognition-$0.48-$0.51-$0.03-$0.51N/AN/A3/20/2025Q4 2024EPRXEupraxia Pharmaceuticals-$0.20-$0.21-$0.01-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AESLAEstrella ImmunopharmaN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A1.501.50EPRXEupraxia PharmaceuticalsN/A4.174.17ESLAEstrella ImmunopharmaN/A0.750.75TILInstil Bio0.4712.9012.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/AEPRXEupraxia PharmaceuticalsN/AESLAEstrella Immunopharma0.35%TILInstil Bio60.56%Insider OwnershipCompanyInsider OwnershipACOGAlpha Cognition14.00%EPRXEupraxia PharmaceuticalsN/AESLAEstrella Immunopharma55.10%TILInstil Bio47.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A16.02 million10.97 millionN/AEPRXEupraxia Pharmaceuticals2935.85 millionN/AN/AESLAEstrella ImmunopharmaN/A36.17 million16.24 millionNot OptionableTILInstil Bio4106.56 million3.49 millionNo DataESLA, ACOG, EPRX, and TIL HeadlinesRecent News About These CompaniesAre You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great ChoiceJune 4 at 1:06 PM | zacks.comInstil Bio appoints new Chief Medical OfficerJune 4 at 1:29 AM | uk.investing.comInstil Bio appoints Jamie Freedman as Chief Medical OfficerJune 2 at 8:10 PM | msn.comInstil Bio, Inc. Appoints Jamie Freedman, M.D., Ph.D., as Chief Medical Officer to Propel Cancer Therapy DevelopmentJune 2 at 7:19 AM | quiverquant.comInstil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical OfficerJune 2 at 7:00 AM | globenewswire.comInstil Bio to Participate in the 2025 Jefferies Global Healthcare ConferenceMay 30, 2025 | globenewswire.comInstil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?May 29, 2025 | zacks.comWall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to TradeMay 29, 2025 | zacks.comInstil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF SuccessMay 25, 2025 | seekingalpha.comInstil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ...May 25, 2025 | morningstar.comInstil Bio stock price target cut to $105 by H.C. WainwrightMay 24, 2025 | uk.investing.comInstil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in ...May 24, 2025 | seekingalpha.comInstil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in ChicagoMay 23, 2025 | globenewswire.comInstil Bio Shares Jump on Trial Updates for Lung Cancer TreatmentMay 23, 2025 | marketwatch.comInstil Bio shares rise on immunotherapy trial updatesMay 23, 2025 | msn.comInstil Bio shares rise after updates on cancer trialsMay 23, 2025 | seekingalpha.comInstil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025May 22, 2025 | globenewswire.comInstil Bio, Inc. Progresses with Ongoing NSCLC Trials for AXN-2510/IMM2510 and Reports Q1 2025 Financial ResultsMay 13, 2025 | quiverquant.comInstil Bio Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 13, 2025 | globenewswire.comInstil Bio reports Q4 adjusted EPS ($1.08) vs. ($1.26) last yearMarch 4, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesUber Stock Ready to Ride Higher on Waymo PartnershipBy Gabriel Osorio-Mazilli | May 28, 2025View Uber Stock Ready to Ride Higher on Waymo PartnershipTesla: Why Analysts Think It Could Jump Another 47%By Sam Quirke | May 27, 2025View Tesla: Why Analysts Think It Could Jump Another 47%Tesla: Get Ready To See It Trading Above $400 AgainBy Sam Quirke | May 14, 2025View Tesla: Get Ready To See It Trading Above $400 AgainMagnificent 7 Stocks Shift Toward Stability and Selective GrowthBy Gabriel Osorio-Mazilli | May 19, 2025View Magnificent 7 Stocks Shift Toward Stability and Selective GrowthAlphabet Stock Lags—But Waymo May Be Its Hidden DriverBy Gabriel Osorio-Mazilli | May 25, 2025View Alphabet Stock Lags—But Waymo May Be Its Hidden DriverESLA, ACOG, EPRX, and TIL Company DescriptionsAlpha Cognition NASDAQ:ACOG$9.05 -0.53 (-5.53%) As of 03:42 PM EasternAlpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.Eupraxia Pharmaceuticals NASDAQ:EPRX$3.94 -0.03 (-0.76%) As of 03:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.Estrella Immunopharma NASDAQ:ESLA$1.08 +0.09 (+8.59%) Closing price 03:59 PM EasternExtended Trading$1.06 -0.01 (-1.40%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.Instil Bio NASDAQ:TIL$30.17 -4.23 (-12.29%) Closing price 03:59 PM EasternExtended Trading$30.24 +0.06 (+0.21%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Guidewire Rockets Higher: A Move Above $300 Is Probable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
